DB
AEGR

Dmitry Balyasny’s Aegerion Pharmaceuticals AEGR Stock Holding History

Dmitry Balyasny’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-194,100
Closed -$5.08M – 1456
2015
Q1 		$5.08M Buy
+194,100
New +$4.94M 0.04% 474

Other funds holding AEGR

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Dmitry Balyasny's AEGR Position: Q2 2016 in Review

Dmitry Balyasny sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 38,172 shares — an estimated $141K sold.

Dmitry Balyasny first reported a position in AEGR in Q2 2013 and held it in 4 quarters. The position peaked at $17.3M in Q1 2015. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Dmitry Balyasny reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Dmitry Balyasny sold 38,172 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $141K.
  • Dmitry Balyasny first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Dmitry Balyasny's Aegerion Pharmaceuticals position peaked at $17.3M in Q1 2015.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Balyasny Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.